Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy

American Journal of Pathology

Volumn 180, Issue 4, 2012, Pages 1593-1602

  Rooney, Jachinta E ^a   Knapp, Jolie R ^a   Hodges, Bradley L ^b   Wuebbles, Ryan D ^a   Burkin, Dean J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b Prothelia Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMININ; LAMININ 111; MEROSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; FEMALE; GRIP STRENGTH; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LIFE EXPECTANCY; MACROPHAGE; MEROSIN DEFICIENT CONGENITAL MUSCULAR DYSTROPHY TYPE 1A; MONOCYTE; MONONUCLEAR CELL; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE CONTRACTION; MUSCLE DEVELOPMENT; MUSCLE DISEASE; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOSITIS; NEUROMUSCULAR DISEASE; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT DURATION; TRICEPS BRACHII MUSCLE; WEIGHT REDUCTION;

ANIMALS; APOPTOSIS; CELL LINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; FIBROSIS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; KAPLAN-MEIER ESTIMATE; LAMININ; MICE; MOTOR ACTIVITY; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MYOBLASTS; MYOSITIS; PROTEIN ISOFORMS; WEIGHT LOSS;

EID: 84859075862     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.12.019     Document Type: Article

References (49)

1. K.J. Jones, G. Morgan, H. Johnston, V. Tobias, R.A. Ouvrier, I. Wilkinson, K.N. North The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review J Med Genet 38 2001 649 657
2. T. Muntoni F Voit The congenital muscular dystrophies in 2004: a century of exciting progress Neuromuscul Disord 14 2004 635 649
3. J. Philpot, F. Cowan, J. Pennock, C. Sewry, V. Dubowitz, G. Bydder, F. Muntoni Merosin-deficient congenital muscular dystrophy: the spectrum of brain involvement on magnetic resonance imaging Neuromuscul Disord 9 1999 81 85
4. J. Philpot, A. Bagnall, C. King, V. Dubowitz, F. Muntoni Feeding problems in merosin deficient congenital muscular dystrophy Arch Dis Child 80 1999 542 547
5. A. Helbling-Leclerc, X. Zhang, H. Topaloglu, C. Cruaud, F. Tesson, J. Weissenbach, F.M. Tome, K. Schwartz, M. Fardeau, K. Tryggvason, P. Guicheney Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy Nat Genet 11 1995 216 218
6. I.S. Naom, M. D'alessandro, H. Topaloglu, C. Sewry, A. Ferlini, A. Helbling-Leclerc, P. Guicheney, J. Weissenbach, K. Schwartz, K. Bushby, J. Philpot, V. Dubowitz, F. Muntoni Refinement of the laminin alpha2 chain locus to human chromosome 6q2 in severe and mild merosin deficient congenital muscular dystrophy J Med Genet 34 1997 99 104
7. D. Gullberg, C.F. Tiger, T. Velling Laminins during muscle development and in muscular dystrophies Cell Mol Life Sci 56 1999 442 460
8. F. Pedrosa-Domellof, C.F. Tiger, I. Virtanen, L.E. Thornell, D. Gullberg Laminin chains in developing and adult human myotendinous junctions J Histochem Cytochem 48 2000 201 210
9. B. Ringelmann, C. Roder, R. Hallmann, M. Maley, M. Davies, M. Grounds, L. Sorokin Expression of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin, and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice Exp Cell Res 246 1999 165 182
10. F. Schuler, L.M. Sorokin Expression of laminin isoforms in mouse myogenic cells in vitro and in vivo J Cell Sci 108 Pt 12 1995 3795 3805
11. T. Sasaki, R. Giltay, U. Talts, R. Timpl, J.F. Talts Expression and distribution of laminin alpha1 and alpha2 chains in embryonic and adult mouse tissues: an immunochemical approach Exp Cell Res 275 2002 185 199
12. M. Aumailley, N. Smyth The role of laminins in basement membrane function J Anat 193 Pt 1 1998 1 21
13. B.L. Patton, J.H. Miner, A.Y. Chiu, J.R. Sanes Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice J Cell Biol 139 1997 1507 1521
14. P.T. Martin, A.J. Ettinger, J.R. Sanes A synaptic localization domain in the synaptic cleft protein laminin beta 2 (s-laminin) Science 269 1995 413 416
15. W. Kuang, H. Xu, J.T. Vilquin, E. Engvall Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency Lab Invest 79 1999 1601 1613
16. P.H. Vachon, F. Loechel, H. Xu, U.M. Wewer, E. Engvall Merosin and laminin in myogenesis; specific requirement for merosin in myotube stability and survival J Cell Biol 134 1996 1483 1497
17. M. Girgenrath, M.L. Beermann, V.K. Vishnudas, S. Homma, J.B. Miller Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy Ann Neurol 65 2009 47 56
18. P.H. Vachon, H. Xu, L. Liu, F. Loechel, Y. Hayashi, K. Arahata, J.C. Reed, U.M. Wewer, E. Engvall Integrins (alpha7beta1) in muscle function and survival Disrupted expression in merosin-deficient congenital muscular dystrophy J Clin Invest 100 1997 1870 1881
19. C.F. Bentzinger, P. Barzaghi, S. Lin, M.A. Ruegg Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice FASEB J 19 2005 934 942
20. S. Meinen, P. Barzaghi, S. Lin, H. Lochmuller, M.A. Ruegg Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages J Cell Biol 176 2007 979 993
21. J.E. Rooney, P.B. Gurpur, Z. Yablonka-Reuveni, D.J. Burkin Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathy Am J Pathol 174 2009 256 264
22. S. Goudenege, Y. Lamarre, N. Dumont, J. Rousseau, J. Frenette, D. Skuk, J.P. Tremblay Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy Mol Ther 18 2010 2155 2163
23. J.E. Rooney, P.B. Gurpur, D.J. Burkin Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy Proc Natl Acad Sci U S A 106 2009 7991 7996
24. R. Xu, K. Chandrasekharan, J.H. Yoon, M. Camboni, P.T. Martin Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A Am J Pathol 171 2007 181 199
25. G.K. Reddy, C.S. Enwemeka A simplified method for the analysis of hydroxyproline in biological tissues Clin Biochem 29 1996 225 229
26. J.V. Welser, J.E. Rooney, N.C. Cohen, P.B. Gurpur, C.A. Singer, R.A. Evans, B.A. Haines, D.J. Burkin Myotendinous junction defects and reduced force transmission in mice that lack alpha7 integrin and utrophin Am J Pathol 175 2009 1545 1554
27. V. Allamand, P. Guicheney Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A. MIM#156225, LAMA2 gene coding for alpha2 chain of laminin) Eur J Hum Genet 10 2002 91 94
28. K. Gawlik, Y. Miyagoe-Suzuki, P. Ekblom, S. Takeda, M. Durbeej Laminin alpha1 chain reduces muscular dystrophy in laminin alpha2 chain deficient mice Hum Mol Genet 13 2004 1775 1784
29. J.R. Mendell, D.R. Boue, P.T. Martin The congenital muscular dystrophies: recent advances and molecular insights Pediatr Dev Pathol 9 2006 427 443
30. E. Pegoraro, P. Mancias, S.H. Swerdlow, R.B. Raikow, C. Garcia, H. Marks, T. Crawford, V. Carver, B. Di Cianno, E.P. Hoffman Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy Ann Neurol 40 1996 782 791
31. K.I. Gawlik, M. Akerlund, V. Carmignac, H. Elamaa, M. Durbeej Distinct roles for laminin globular domains in laminin alpha1 chain mediated rescue of murine laminin alpha2 chain deficiency PLoS One 5 2010 e11549
32. R. Nishiuchi, J. Takagi, M. Hayashi, H. Ido, Y. Yagi, N. Sanzen, T. Tsuji, M. Yamada, K. Sekiguchi Ligand-binding specificities of laminin-binding integrins: a comprehensive survey of laminin-integrin interactions using recombinant alpha3beta1, alpha6beta1, alpha7beta1 and alpha6beta4 integrins Matrix Biol 25 2006 189 197
33. J.F. Talts, Z. Andac, W. Gohring, A. Brancaccio, R. Timpl Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins EMBO J 18 1999 863 870
34. Y. Taniguchi, H. Ido, N. Sanzen, M. Hayashi, R. Sato-Nishiuchi, S. Futaki, K. Sekiguchi The C-terminal region of laminin beta chains modulates the integrin binding affinities of laminins J Biol Chem 284 2009 7820 7831
35. H. Yamada, T. Shimizu, T. Tanaka, K.P. Campbell, K. Matsumura Dystroglycan is a binding protein of laminin and merosin in peripheral nerve FEBS Lett 352 1994 49 53
36. W. Kuang, H. Xu, P.H. Vachon, L. Liu, F. Loechel, U.M. Wewer, E. Engvall Merosin-deficient congenital muscular dystrophy Partial genetic correction in two mouse models J Clin Invest 102 1998 844 852
37. L.M. Sorokin, F. Pausch, M. Durbeej, P. Ekblom Differential expression of five laminin alpha (15) chains in developing and adult mouse kidney Dev Dyn 210 1997 446 462
38. I. Virtanen, D. Gullberg, J. Rissanen, E. Kivilaakso, T. Kiviluoto, L.A. Laitinen, V.P. Lehto, P. Ekblom Laminin alpha1-chain shows a restricted distribution in epithelial basement membranes of fetal and adult human tissues Exp Cell Res 257 2000 298 309
39. A. Kumar, J. Yamauchi, T. Girgenrath, M. Girgenrath Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A Hum Mol Genet 20 2011 2333 2343
40. J.A. Doe, R.D. Wuebbles, E.T. Allred, J.E. Rooney, M. Elorza, D.J. Burkin Transgenic overexpression of the {alpha}7 integrin reduces muscle pathology and improves viability in the dyW mouse model of merosin-deficient congenital muscular dystrophy type 1A J Cell Sci 124 2011 2287 2297
41. M. Girgenrath, J.A. Dominov, C.A. Kostek, J.B. Miller Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy J Clin Invest 114 2004 1635 1639
42. M. Erb, S. Meinen, P. Barzaghi, L.T. Sumanovski, I. Courdier-Fruh, M.A. Ruegg, T. Meier Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency J Pharmacol Exp Ther 331 2009 787 795
43. V. Carmignac, M. Svensson, Z. Korner, L. Elowsson, C. Matsumura, K. Gawlik, V. Allamand, M. Durbeej Autophagy is increased in laminin α2 chain deficient muscle and inhibition improves muscle morphology in a mouse model of MDC1A Hum Mol Genet 20 2011 4891 4902
44. K.J. Sonnemann, H. Heun-Johnson, A.J. Turner, K.A. Baltgalvis, D.A. Lowe, J.M. Ervasti Functional substitution by TAT-utrophin in dystrophin-deficient mice PLoS Med 6 2009 e1000083
45. A.R. Amenta, A. Yilmaz, S. Bogdanovich, B.A. McKechnie, M. Abedi, T.S. Khurana, J.R. Fallon Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice Proc Natl Acad Sci U S A 108 2011 762 767
46. Q.L. Lu, T. Yokota, S. Takeda, L. Garcia, F. Muntoni, T. Partridge The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy Mol Ther 19 2011 9 15
47. B. Rippe, B.I. Rosengren, O. Carlsson, D. Venturoli Transendothelial transport: the vesicle controversy J Vasc Res 39 2002 375 390
48. R. Rojas, G. Apodaca Immunoglobulin transport across polarized epithelial cells Nat Rev Mol Cell Biol 3 2002 944 955
49. V. Straub, J.A. Rafael, J.S. Chamberlain, K.P. Campbell Animal models for muscular dystrophy show different patterns of sarcolemmal disruption J Cell Biol 139 1997 375 385